Cencora (NYSE:COR) Shares Acquired Rep. Jared Moskowitz

Key Points

• Representative Jared Moskowitz disclosed a purchase of $1,001–$15,000 in Cencora (NYSE:COR) shares on March 31 in his Morgan Stanley Active Assets account, and executed several other trades that same day across major names.
• Cencora shares opened at $304.18 (down about 1.2%), the company has a market cap of $59.17B and a 12‑month range of $271–$377.54; last quarter EPS was $4.08 (beat $4.04) while revenue of $85.93B was slightly below estimates.
• Analysts are generally bullish—12 Buys and 3 Holds with an average price target of $398.17 (Wells Fargo at $429)—and the company pays a quarterly dividend of $0.60 (annualized $2.40, ~0.8% yield).

Representative Jared Moskowitz (Democratic-Florida) recently bought shares of Cencora, Inc. NYSE: COR. In a filing disclosed on April 30th, the Representative disclosed that they had bought between $1,001 and $15,000 in Cencora stock on March 31st. The trade occurred in the Representative's "MORGAN STANLEY ACTIVE ASSETS (1)" account.

Representative Jared Moskowitz also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Caterpillar NYSE: CAT on 3/31/2026.
• Purchased $1,001 - $15,000 in shares of Palo Alto Networks NASDAQ: PANW on 3/31/2026.
• Purchased $1,001 - $15,000 in shares of McDonald's NYSE: MCD on 3/31/2026.
• Purchased $1,001 - $15,000 in shares of GE Aerospace NYSE: GE on 3/31/2026.
• Sold $15,001 - $50,000 in shares of Qualcomm NASDAQ: QCOM on 3/31/2026.
• Purchased $1,001 - $15,000 in shares of American Express NYSE: AXP on 3/31/2026.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 3/31/2026.
• Purchased $1,001 - $15,000 in shares of Chubb NYSE: CB on 3/31/2026.
• Sold $1,001 - $15,000 in shares of Cummins NYSE: CMI on 3/31/2026.
• Purchased $1,001 - $15,000 in shares of General Dynamics NYSE: GD on 3/31/2026.

Cencora Stock Down 1.2%

COR stock opened at $304.18 on Friday. Cencora, Inc. has a 12 month low of $271.00 and a 12 month high of $377.54. The firm has a market cap of $59.17 billion, a PE ratio of 36.56, a P/E/G ratio of 1.44 and a beta of 0.65. The firm has a 50 day simple moving average of $333.36 and a 200 day simple moving average of $342.95. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business had revenue of $85.93 billion during the quarter, compared to analyst estimates of $86.12 billion. During the same period in the prior year, the business earned $3.73 earnings per share. The business's quarterly revenue was up 5.5% on a year-over-year basis. Equities research analysts forecast that Cencora, Inc. will post 17.56 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, February 13th. This represents a $2.40 annualized dividend and a yield of 0.8%. Cencora's dividend payout ratio is currently 28.85%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Kemnay Advisory Services Inc. acquired a new position in Cencora in the 4th quarter valued at $25,000. Oakworth Capital Inc. bought a new stake in Cencora in the 4th quarter valued at $26,000. Elyxium Wealth LLC bought a new stake in Cencora in the 4th quarter valued at $27,000. Archer Investment Corp boosted its holdings in Cencora by 134.3% in the 4th quarter. Archer Investment Corp now owns 82 shares of the company's stock valued at $28,000 after purchasing an additional 47 shares during the period. Finally, Motiv8 Investments LLC bought a new stake in Cencora in the 4th quarter valued at $29,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Robert W. Baird set a $415.00 target price on shares of Cencora in a research note on Tuesday, January 13th. Wells Fargo & Company increased their target price on shares of Cencora from $405.00 to $429.00 and gave the company an "overweight" rating in a research note on Tuesday, February 10th. Leerink Partners reissued an "outperform" rating on shares of Cencora in a research note on Tuesday, March 17th. Evercore set a $360.00 price target on shares of Cencora in a research report on Wednesday, April 8th. Finally, Weiss Ratings upgraded shares of Cencora from a "hold (c+)" rating to a "buy (b)" rating in a research report on Thursday, February 5th. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $398.17.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida's 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida's 23rd Congressional District. He declared candidacy for the 2026 election. Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor's degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz's career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

About Cencora

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.